Pharmaceutical

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

12 months ago

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI),…

12 months ago

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical…

12 months ago

Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer

Seattle, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted therapies…

12 months ago

Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

Company to host an investor conference call and webcast at 4:30pm EDTNEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia,…

12 months ago

MBX Biosciences Announces U.S. FDA Clearance of IND Application for MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Phase 1 trial initiation anticipated Q3 2023; Topline results expected in 2H 2024CARMEL, Ind., Aug. 07, 2023 (GLOBE NEWSWIRE) --…

12 months ago

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers…

12 months ago

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access…

12 months ago

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…

12 months ago

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

12 months ago